TCR Therapy Market to reach USD 1.09 Bn by 2032

The global TCR therapy market size is currently valued at USD 0.06 billion in 2025. It is poised to reach a USD 1.09 billion valuation by 2032, displaying a CAGR of 51.3% during the forecast period (2025-2032).  

The high prevalence of cancer cases and a strong clinical pipeline of resistant drugs and therapies to battle cancers are major drivers of the market growth. The development of T-cell receptor (TCR) therapies and collaborations between biopharmaceutical companies for the development of new scientific breakthroughs can bolster the market growth.

However, the exorbitant costs of manufacturing of personalized cancer treatments can hamper demand.

The TCR therapy market demand is expected to surge owing to clinical trial approvals by regulatory bodies, massive demand for the treatment of solid tumors, and fundraising by venture capital firms for TCR therapies.

The use of cell therapies for the development of immune cells from healthy donors is expected to drive the TCR therapy market growth. This is bolstered by the approval of chimeric antigen receptor (CAR) natural killer cell therapies for patients with B-cell lymphomas and leukemias.

Active clinical trials exploring therapies in kidney, lung, ovarian, and pancreatic cancers are expected to induce significant market demand. In February 2025, a phase I trial of a neoantigen vaccine for the treatment of advanced kidney cancer at Dana-Farber Cancer Institute showed all patients cleared of cancer after 35 months of follow-up. This can culminate in the development of personalized treatments for cancer patients in the coming years.

Strategic collaborations and partnerships between biopharmaceutical companies and cell engineering firms are expected to encourage the development of next-generation cell therapies. In October 2024, Nona Biosciences collaborated with OverT Bio for the development of cell therapies for the treatment of solid tumors.

The use of allogeneic therapies instead of autologous cell therapies for the treatment of advanced cancers is likely to drive investments from venture capital firms. This is illustrated by the partnership between Moderna, Inc. and Immatics N.V. for the development of T-cell redirecting cancer immunotherapies in September 2023. Immatics gained USD 120 million and expects to secure USD 1.7 billion in milestone payments.

The multi-step process required for the development of a TCR therapy to be administered to a patient increases its manufacturing cost significantly. The long manufacturing times and involvement of multiple personnel to ensure its efficacy add to production costs. Alternative manufacturing processes to lower costs can address this challenge.

CARsgen Therapeutic Holdings Limited announced the launch of KJ-C2320, a novel allogeneic CAR T-cell therapy targeting CD38, a multifunctional glycoprotein expressed on some cancer cells, in January 2025. It has been administered to a patient with relapsed/refractory acute myeloid leukemia.